Non-pharmacological Rehabilitation Interventions for Individuals with Antiphospholipid Syndrome: A Scoping Review

Overview

Journal Lupus

Publisher Sage Publications

Specialty Rheumatology

Date 2023 Dec 19

PMID 38113856

Authors

Alexandra E Harper

Yen T Chen

Stephanie Tancer

Kyla R Rodgers

Amber D Crumb

Whitney A Townsend

Jason S Knight

Susan L Murphy

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to explore what non-pharmacological interventions have been examined for individuals with antiphospholipid syndrome (APS).

Methods: We conducted a systematic literature search of the databases PubMed, Embase, Scopus, Web of Science, CINAHL, and ClinicalTrials.gov from 1983-Feb. 2023. Our scoping review included studies that examined non-pharmacological interventions for individuals with APS using patient-reported outcome measures. We excluded studies that reported physiological outcomes only.

Results: The review yielded one case study on the safety and efficacy of an exercise program for a 15-year-old male with secondary APS using physiological and patient-reported outcome measures. Despite the lack of evidence of non-pharmacological interventions for individuals with APS, one excluded study reported that individuals with APS want guidance about physical activity and exercise. We also found several types of potentially relevant non-pharmacological interventions for individuals with lupus, a disease that often co-occurs with APS.

Conclusions: Non-pharmacological interventions may offer a solution for addressing some non-thrombotic or non-obstetric APS symptoms, such as neurological, physical, and cognitive symptoms that are not well-controlled by anticoagulation. Due to the unique risks associated with APS, research is needed to determine the safety and efficacy of non-pharmacological interventions, particularly those involving exercise. Adopting a comprehensive, multidisciplinary approach to managing patients with APS and involving rehabilitation professionals, who are experts in the design and delivery of non-pharmacological interventions, may provide a foundation for developing and testing novel interventions that improve health outcomes while also fulfilling unmet needs reported by patients.

Citing Articles

Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.

Zhang Z, Wang Z, Du X, Huang X, Zhang Y J Neurol. 2023; 271(1):584-588.

PMID: 37804335 DOI: 10.1007/s00415-023-12036-y.

References

Williams E, Egede L, Faith T, Oates J . Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring. Am J Med Sci. 2017; 353(6):580-592. PMC: 6249683. DOI: 10.1016/j.amjms.2017.01.011. View

Rolving N, Brocki B, Andreasen J . Coping with everyday life and physical activity in the aftermath of an acute pulmonary embolism: A qualitative study exploring patients' perceptions and coping strategies. Thromb Res. 2019; 182:185-191. DOI: 10.1016/j.thromres.2019.06.007. View

Sammaritano L . Antiphospholipid syndrome. Best Pract Res Clin Rheumatol. 2019; 34(1):101463. DOI: 10.1016/j.berh.2019.101463. View

Pinto S, Yassin M, Galang G . Cost-Effectiveness Analysis of Routine Venous Doppler Ultrasound for Diagnosis of Deep Venous Thrombosis at Admission to Inpatient Rehabilitation. Am J Phys Med Rehabil. 2018; 97(10):747-753. DOI: 10.1097/PHM.0000000000000961. View

Ambrosetti M, Abreu A, Corra U, Davos C, Hansen D, Frederix I . Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2021; 28(5):460-495. DOI: 10.1177/2047487320913379. View

Garcia C, Seguro L, Perandini L, de Sa Pinto A, Rodrigues Lima F, Negrao C . Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin. Rheumatol Int. 2014; 34(12):1737-41. DOI: 10.1007/s00296-014-3038-7. View

Tricco A, Lillie E, Zarin W, OBrien K, Colquhoun H, Kastner M . A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016; 16:15. PMC: 4746911. DOI: 10.1186/s12874-016-0116-4. View

Hwang J, Shin S, Kim Y, Oh Y, Lee S, Kim Y . Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study. J Korean Med Sci. 2020; 35(5):e35. PMC: 7008065. DOI: 10.3346/jkms.2020.35.e35. View

Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S . Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2022; 81(1):16-30. PMC: 9812926. DOI: 10.1016/j.jacc.2022.10.008. View

10.

Michael Clark J, Sanders S, Carter M, Honeyman D, Cleo G, Auld Y . Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial. J Med Libr Assoc. 2020; 108(2):195-207. PMC: 7069833. DOI: 10.5195/jmla.2020.834. View

11.

Arnson Y, Shoenfeld Y, Alon E, Amital H . The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum. 2009; 40(2):97-108. DOI: 10.1016/j.semarthrit.2009.05.001. View

12.

Brier N . Understanding and managing the emotional reactions to a miscarriage. Obstet Gynecol. 1999; 93(1):151-5. DOI: 10.1016/s0029-7844(98)00294-4. View

13.

ODwyer T, Durcan L, Wilson F . Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. Semin Arthritis Rheum. 2017; 47(2):204-215. DOI: 10.1016/j.semarthrit.2017.04.003. View

14.

Dabit J, Valenzuela-Almada M, Vallejo-Ramos S, Duarte-Garcia A . Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep. 2022; 23(12):85. PMC: 8727975. DOI: 10.1007/s11926-021-01038-2. View

15.

Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou M . Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository. Arthritis Care Res (Hoboken). 2020; 74(2):324-335. PMC: 10725727. DOI: 10.1002/acr.24468. View

16.

Garcia C, Perandini L, Seguro L, Gualano B, Roschel H, Bonfa E . Impaired aerobic exercise capacity and cardiac autonomic control in primary antiphospholipid syndrome. Lupus. 2013; 22(9):928-31. DOI: 10.1177/0961203313497415. View

17.

Ruiz-Irastorza G, Egurbide M, Ugalde J, Aguirre C . High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004; 164(1):77-82. DOI: 10.1001/archinte.164.1.77. View

18.

Tenedios F, Erkan D, Lockshin M . Cardiac involvement in the antiphospholipid syndrome. Lupus. 2005; 14(9):691-6. DOI: 10.1191/0961203305lu2202oa. View

19.

Brick R, Padgett L, Jones J, Wood K, Pergolotti M, Marshall T . The influence of telehealth-based cancer rehabilitation interventions on disability: a systematic review. J Cancer Surviv. 2022; 17(6):1725-1750. PMC: 8881759. DOI: 10.1007/s11764-022-01181-4. View

20.

Riancho-Zarrabeitia L, Martinez-Taboada V, Rua-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J . Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus. 2020; 29(12):1556-1565. DOI: 10.1177/0961203320950477. View